Plain-English translation of NCT06915389 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This research study is looking at blood samples from gastric cancer patients who are receiving PD-1/PD-L1 inhibitor immunotherapy. Researchers want to find specific patterns in your blood — looking at molecules and fats — that could predict whether you'll develop serious side effects from this medication. By identifying these patterns early, doctors hope to better manage your treatment and improve your overall care.
Some patients receiving this immunotherapy develop serious side effects, but doctors currently cannot predict who will be affected. This study aims to find early biological warning signs in your blood so doctors can catch and manage these side effects before they become severe.
You likely qualify if…
You likely don't qualify if…
You will have blood samples collected before you start immunotherapy and then at specific timepoints as you receive your treatment. If you develop side effects, an additional sample will be taken when those symptoms first appear. Researchers will also collect information about any side effects you experience and how they affect your quality of life. The study compares blood samples from patients who develop side effects with those who do not, to identify the key biological differences.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
China
Sponsor
Qinghai Red Cross Hospital
Enrollment target
~100 participants
Started
February 2025
Primary completion
December 2026
Age range
18 Years – 80 Years
Last updated on clinicaltrials.gov in April 2025.
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.